Tranexamic acid for trauma: Filling the 'GAP' in evidence

EMA - Emergency Medicine Australasia

Volumn 26, Issue 2, 2014, Pages 194-197

  Mitra, Biswadev ^a,b   Mazur, Stefan ^c,d,e   Cameron, Peter A ^a,b   Bernard, Stephen ^b,f   Burns, Brian ^g,h,i   Smith, Anthony ^j,k   Rashford, Stephen ^l,m   Fitzgerald, Mark ^a,f   Smith, Karen ^b,f,n   Gruen, Russell L ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c South Australia Ambulance Service   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e JAMES COOK UNIVERSITY   (Australia)

^f Blackburn North   (Australia)

^g LIVERPOOL HOSPITAL   (Australia)

^h Greater Sydney Area Helicopter Emergency Medical Service Ambulance Service New South Wales Rescue Helicopter Base Bankstown Airport   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j St John Ambulance Association   (New Zealand)

^k AUCKLAND CITY HOSPITAL   (New Zealand)

^l Queensland Government Department of Emergency Services   (Australia)

^m ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁿ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

Evidence based practice; Haemorrhage; Resuscitation; Tranexamic acid; Wounds and injuries

Indexed keywords

TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; HUMAN; INJURY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; COMPLICATION; EVIDENCE BASED MEDICINE; HEMORRHAGE; MULTIPLE TRAUMA; PROCEDURES;

ANTIFIBRINOLYTIC AGENTS; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; MULTIPLE TRAUMA; RESUSCITATION; TRANEXAMIC ACID;

EID: 84897949335     PISSN: 17426731     EISSN: 17426723     Source Type: Journal    
DOI: 10.1111/1742-6723.12172     Document Type: Article

References (20)

1. Meybohm P, Herrmann E, Nierhoff J, Zacharowski K. Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and epsilon-aminocaproic acid - a meta-analysis of randomised and observational trials of over 30.000 patients. PLoS ONE 2013; 8: e58009.
2. Zhou XD, Tao LJ, Li J, Wu LD. Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials. Arch. Orthop. Trauma Surg. 2013; 133: 1017-1027.
3. Cooke I, Lethaby A, Farquhar C. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2000; CD000249.
4. Costa FW, Rodrigues RR, Sousa LH etal. Local hemostatic measures in anticoagulated patients undergoing oral surgery: a systematized literature review. Acta Cir. Bras. 2013; 28: 78-83.
5. Shakur H, Roberts I, Bautista R etal. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
6. Dekkers OM, von Elm E, Algra A, Romijn JA, Vandenbroucke JP. How to assess the external validity of therapeutic trials: a conceptual approach. Int. J. Epidemiol. 2010; 39: 89-94.
7. Fernandez-Hermida JR, Calafat A, Becoña E, Tsertsvadze A, Foxcroft DR. Assessment of generalizability, applicability and predictability (GAP) for evaluating external validity in studies of universal family-based prevention of alcohol misuse in young people: systematic methodological review of randomized controlled trials. Addiction 2012; 107: 1570-1579.
8. Pusateri AE, Weiskopf RB, Bebarta V etal. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock 2013; 39: 121-126.
9. Levy JH, Pifarre R, Schaff HV etal. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92: 2236-2244.
10. Fergusson DA, Hébert PC, Mazer CD etal. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N. Engl. J. Med. 2008; 358: 2319-2331.
11. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch. Surg. 2012; 147: 113-119.
12. Roberts I. Do animal experiments inform patient care? [Cited March 2014.] Available from URL: http://www.youtube.com/watch?v=S5gJRRLWLKU
13. Mitra B, Cameron PA, Gruen RL. Aggressive fresh frozen plasma (FFP) with massive blood transfusion in the absence of acute traumatic coagulopathy. Injury 2012; 43: 33-37.
14. Mitra B, Cameron PA, Mori A, Fitzgerald M. Acute coagulopathy and early deaths post major trauma. Injury 2012; 43: 22-25.
15. Gruen RL, Mitra B. Tranexamic acid for trauma. Lancet 2011; 377: 1052-1054.
16. Robertshaw HJ. An anti-inflammatory role for tranexamic acid in cardiac surgery? Crit. Care 2008; 12: 105.
17. Fernandez LA, Garrido-Martin EM, Sanz-Rodriguez F etal. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb. Haemost. 2007; 97: 254-262.
18. Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE. Tranexamic acid in trauma: how should we use it? J. Trauma Acute Care Surg. 2013; 74: 1575-1586.
19. PATCH-Trauma Study Investigators. PATCH-Trauma study. 2013 [Cited Oct 2013.] Available from URL: http://patchtrauma.org/
20. Mitra B, Cameron PA, Mori A etal. Early prediction of acute traumatic coagulopathy. Resuscitation 2011; 82: 1208-1213.